Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Curing What Ails Alzheimer’s Drug Development

Jan 03 2018

• By Rachel Laing, Alessia Deglincerti, and Mark Ratner

Related Content

Alzheimer's Prevention: The Next Big Idea For Fixing Drug Trial Failures

Sep 28 2017

Disappointed, Yes, But Roivant's Not Roiled By Axovant's Alzheimer's Failure

Sep 27 2017

Gates Injects UK-US Dementia Discovery Fund With $50m And Fresh Purpose

Nov 14 2017

AbbVie Goes Boldly Into Immuno-Neurology With Alector

Oct 24 2017

A Status Check Of The Alzheimer’s Trial Landscape

Dec 01 2017

Lilly’s Solanezumab Fails, But The Surprise Would Have Been Success

Nov 23 2016

Another Nail In Amyloid Hypothesis Coffin? Merck Ends Pivotal BACE Inhibitor Study

Feb 15 2017

Amgen, Novartis May Screen 30,000 Patients To Find 2,000 For Alzheimer's Trial

Nov 02 2017

Related Companies

Sio Gene Therapies, Inc.

Merck & Co., Inc.

Pfizer Inc.

Johnson & Johnson

Johnson & Johnson

Eli Lilly and Company

Biogen, Inc.

Roche Holding AG

Voyager Therapeutics, Inc

AstraZeneca PLC

National Institutes of Health

Washington University School of Medicine

Genentech, Inc.

Eli Lilly and Company

Novartis AG

AbbVie Inc.

Alector, Inc.

Additional Topics

Business Strategies Innovation BioPharmaceutical Neurology

More from Business Strategy

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window